Astragaloside IV alleviates neuronal ferroptosis in ischemic stroke by regulating fat mass and obesity‐associated—N6‐methyladenosine—acyl‐CoA synthetase long‐chain family member 4 axis

Ischemic stroke (IS) is a detrimental neurological disease with limited treatment options. Astragaloside IV (As‐IV) was a promising bioactive constituent in the treatment of IS. However, the functional mechanism remains unclear. Here, IS cell and mouse models were established by oxygen glucose deprivation/re‐oxygenation (OGD/R) and middle cerebral artery occlusion (MCAO). Quantitative reverse transcription PCR (RT–qPCR), Western blotting, or Immunofluorescence staining measured related gene and protein expression of cells or mice brain tissues, and the results revealed altered expression of acyl‐CoA synthetase long‐chain family member 4 (Acsl4), fat mass and obesity‐associated (Fto), and activation transcription factor 3 (Atf3) after treatment with As‐IV. Then, increased N6‐methyladenosine (m6A) levels caused OGD/R or MCAO were reduced by As‐IV according to the data from methylated RNA immunoprecipitation (MeRIP)‐qPCR and dot blot assays. Moreover, through a series of functional experiments such as observing mitochondrial changes under transmission electron microscopy (TEM), evaluating cell viability by cell counting kit‐8 (CCK‐8), analyzing infract area of brain tissues by 2,3,5‐triphenyltetrazolium chloride (TTC) staining, measuring levels of malondialdehyde (MDA), lactate dehydrogenase (LDH), Fe2+, solute carrier family 7 member 11 (Slc7a11) and glutathione peroxidase 4 (Gpx4) and concentration of glutathione (GSH), we found that Fto knockdown, Acsl4 overexpression or Atf3 knockdown promoted the viability of OGD/R cells, inhibited cell ferroptosis, reduced infract size, while As‐IV treatment or Fto overexpression reversed these changes. In mechanism, the interplays of YTH N6‐methyladenosine RNA‐binding protein 3 (Ythdf3)/Acsl4 and Atf3/Fto were analyzed by RNA‐pull down, RNA immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP) and dual‐luciferase reporter assay. Fto regulated the m6A levels of Acsl4. Ythdf3 bound to Acsl4, and modulated its levels through m6A modification. Atf3 bound to Fto and positively regulated its levels. Overall, As‐IV promoted the transcription of Fto by upregulating Atf3, resulting in decreased m6A levels of Acsl4, thus, improving neuronal injury in IS by inhibiting ferroptosis. Ischemic stroke (IS) is a detrimental neurological disease with limited treatments options. Astragaloside IV (As‐IV) was a promising bioactive constituent in the treatment of IS. In our study, As‐IV promoted the transcription of fat mass and o